Even though CML patients achieve disease remission with TK inhibitors (TKIs), they are often committed to a life-long treatment since LSCs may persist and potentially drive disease evolution from chronic phase (CP) to blast crisis (BC). This evidence concerns the gene TKT and chronic myelogenous leukemia, BCR-ABL1 positive.